Frequently asked questions

  • How might FoundationOne® or FoundationOne® Heme be useful in my practice?
    FoundationOne and FoundationOne Heme identify and report genomic alterations that can guide informed treatment recommendations for targeted therapies, either approved or in clinical trials. They identify alterations within hundreds of relevant cancer genes with extremely high sensitivity and specificity.
  • Who is eligible for the FoundationOne® test?
    FoundationOneis available for any patient with a malignant solid tumour. It may reveal additional relevant treatment options to consider based on the molecular profile of the tumour or may help provide additional information for patients who are searching for clinical trial options.
  • Who is eligible for the FoundationOne® Heme test?
    FoundationOne Heme is available for patients with hematologic malignancies and sarcomas. It may reveal additional treatment options to consider based on the genomic factors driving a patient's cancer.
  • How do I order FoundationOne® ?
    The ordering process may differ across countries – please contact our customer services team: Phone: +971 4 816 4900 Email:
  • What are the specimen requirements for FoundationOne® ?
    Click here to download detailed specimen requirements.
  • How do I order FoundationOne® Heme?
    FoundationOne Heme utilises both routine FFPE samples, which may be available from a previous biopsy or surgery, and peripheral whole blood or bone marrow aspirate specimens. We have made the ordering process as simple as possible. The ordering process may differ across countries – please contact our customer services team: Phone: +971 4 816 4900 Email:
  • How long does it take to get results?
    Your office will receive a report 11–14 days after Foundation Medicine receives your patient's sample for FoundationOne. The turnaround time may be slightly longer for FoundationOne Heme. Please note this does not include the time taken to retrieve and send the sample to FMI.
  • How do I obtain the results?
    We will send the results via e-mail, and you may also access reports and links to additional information through the Interactive Cancer Explorer. This secure, online resource provides current information about genomic alterations, associated therapies and clinical trials; all curated by genomic experts in oncology and pathology. It connects directly to resources like, PubMed and other online references to give you the supporting information you need to make treatment recommendations tailored to each patient. The Interactive Cancer Explorer is available for ordering physicians. Please contact your Roche sales representative or call Client Services at +971 4 816 4900 to set up your Interactive Cancer Explorer account.
  • Do these tests predicts response to chemotherapy or the likelihood of recurrence?
    No, these tests were not designed to predict response to chemotherapy or recurrence. They help match the genomic alterations present in a cancer with specific targeted therapies either approved and launched or being investigated in clinical trials.
  • Who can I contact if I have additional questions?
    You may contact the Roche Molecular Information Customer Services Team: Phone: +971 4 816 4900 Email: Operating hours:Monday through Friday, 8:30 AM to 5PM CEST/CET